|
Market Closed -
Nasdaq
16:00:00 2026-11-06 EST
|
5-day change | 1st Jan Change | ||
| 166.89 USD | -0.41% |
|
-2.22% | +35.97% |
| 11-06 | Gilead Sciences Says Twice-Yearly Lenacapavir Shows Higher PrEP Persistence in Phase 2 Trial | MT |
| 11-05 | Maxim Adjusts Price Target on Gilead Sciences to $200 From $165 | MT |
Company Valuation: Gilead Sciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 91,081 | 107,677 | 100,942 | 115,118 | 152,281 | 207,000 | - | - |
| Change | - | 18.22% | -6.25% | 14.04% | 32.28% | 35.93% | - | - |
| Enterprise Value (EV) 1 | 118,530 | 126,522 | 118,665 | 131,838 | 169,585 | 228,272 | 218,612 | 208,664 |
| Change | - | 6.74% | -6.21% | 11.1% | 28.63% | 34.61% | -4.23% | -4.55% |
| P/E | 14.7x | 23.6x | 18x | 243x | 18.1x | -39.2x | 20.1x | 18.7x |
| PBR | 4.32x | 5.05x | 4.48x | 5.98x | 6.73x | 15.5x | 10.7x | 7.9x |
| PEG | - | -0.9x | 0.8x | -2.7x | 0x | 0x | -0x | 2.44x |
| Capitalization / Revenue | 3.34x | 3.95x | 3.72x | 4x | 5.17x | 6.6x | 6.17x | 5.94x |
| EV / Revenue | 4.34x | 4.64x | 4.38x | 4.59x | 5.76x | 7.28x | 6.52x | 5.98x |
| EV / EBITDA | 8.12x | 8.86x | 9.01x | 11.7x | 10.6x | 45.8x | 11.4x | 11x |
| EV / EBIT | 9.45x | 10.4x | 11.3x | 15.5x | 12.9x | 98x | 13.3x | 12x |
| EV / FCF | 11x | 15.2x | 16x | 12.8x | 17.9x | 58.3x | 16.2x | 15x |
| FCF Yield | 9.12% | 6.59% | 6.25% | 7.82% | 5.58% | 1.71% | 6.18% | 6.69% |
| Dividend per Share 2 | 2.84 | 2.92 | 3 | 3.08 | 3.16 | 3.303 | 3.376 | 3.094 |
| Rate of return | 3.91% | 3.4% | 3.7% | 3.33% | 2.57% | 1.98% | 2.02% | 1.85% |
| EPS 2 | 4.93 | 3.64 | 4.5 | 0.38 | 6.78 | -4.26 | 8.291 | 8.926 |
| Distribution rate | 57.6% | 80.2% | 66.7% | 811% | 46.6% | -77.5% | 40.7% | 34.7% |
| Net sales 1 | 27,305 | 27,281 | 27,116 | 28,754 | 29,443 | 31,364 | 33,554 | 34,868 |
| EBITDA 1 | 14,598 | 14,283 | 13,177 | 11,287 | 15,953 | 4,982 | 19,195 | 18,943 |
| EBIT 1 | 12,548 | 12,180 | 10,484 | 8,520 | 13,193 | 2,329 | 16,460 | 17,337 |
| Net income 1 | 6,225 | 4,592 | 5,665 | 480 | 8,510 | -5,292 | 10,697 | 11,301 |
| Net Debt 1 | 27,449 | 18,845 | 17,723 | 16,720 | 17,304 | 21,272 | 11,612 | 1,664 |
| Reference price 2 | 72.61 | 85.85 | 81.01 | 92.37 | 122.74 | 166.89 | 166.89 | 166.89 |
| Nbr of stocks (in thousands) | 1,254,384 | 1,254,244 | 1,246,042 | 1,246,266 | 1,240,680 | 1,240,339 | - | - |
| Announcement Date | 2/1/22 | 2/2/23 | 2/6/24 | 2/11/25 | 2/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -39.95x | 7.29x | 45.82x | 1.98% | 207B | |
| 39.62x | 13.42x | 28.51x | 0.5% | 1,206B | |
| 40.43x | 6.79x | 19.09x | 1.93% | 665B | |
| 37.45x | 8.51x | 17.57x | 2.38% | 515B | |
| 20.98x | 5.12x | 12.74x | 2.57% | 381B | |
| 97.18x | 5.95x | 25.33x | 2.32% | 362B | |
| 23.18x | 5.95x | 14.36x | 2.69% | 307B | |
| 24.46x | 4.89x | 13.77x | 1.79% | 289B | |
| 23.66x | 7.32x | 13.53x | 2.19% | 249B | |
| 11.75x | 4.21x | 8.34x | 4.18% | 177B | |
| Average | 27.88x | 6.94x | 19.91x | 2.25% | 435.69B | |
| Weighted average by Cap. | 34.65x | 8.38x | 21.31x | 1.83% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GILD Stock
- Valuation Gilead Sciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
